Cardiac Resynchronisation


Is There a Future for Remote Cardiac Implantable Electronic Device Management?

Remote follow-up and monitoring of patients implanted with cardiac implantable electronic devices (CIEDs) has been introduced over a decade ago, and is now indicated according to European (class IIa indication1) and American (class I indication2) guidelines. There have been high expectations that this technology will improve patient outcome, as it significantly shortens response to actionable events (e.g. AF) compared with standard in-office follow-up.3,4 However, several randomised trials have failed to meet this promise.5,6

Chagas Heart Failure in Patients from Latin America

More than a century after its discovery, Chagas disease still is a major health problem in Latin America, with 5.7 million people in 21 countries being affected by it.1 Moreover, about 70 million people are at risk of acquiring the illness.1 Cases of Chagas disease are now found globally; there are more than 400,000 immigrants with this disease living in Europe (mainly in Spain, Italy and France) and the United States.2 The consequence of this is that the annual global (direct plus indirect) cost of the disease is in the region of US $7.2 b

Pacing and Defibrillators in Complex Congenital Heart Disease

Device therapy is increasingly employed in the management of complex congenital heart disease (CHD). Bradycardias, most often related to sinus nodal dysfunction (SND) or atrioventricular nodal (AVN) block, may necessitate the implantation of pacing devices, while malignant arrhythmias may be treated by appropriate use of implantable cardioverter defibrillators (ICDs). However, there is a complex interplay between these classical device indications and associated supraventricular tachyarrhythmias, failure of ventricular function and ventricular dyssynchrony.

Cardiac Resynchronisation Therapy and Heart Failure: Perspective from 5P Medicine

The prevalence of heart failure (HF) is still high1 and is rising in developing countries.2 Despite optimal medical therapy, refractory HF is a common occurrence and remains a “global disease requiring global response.”3 The emergence of cardiac resynchronisation therapy (CRT), has brought a new paradigm in the management of HF.

Body Surface Electrocardiographic Mapping for Non-invasive Identification of Arrhythmic Sources

The structural and/or functional abnormality of the cardiac electrovascular system is the most common cause of world mortality accounting for 29.0 % of deaths, followed by infectious diseases (16.2 %) and cancers (12.6 %) (WHO 2008 report). 1 Abnormalities in the cardiac electrical system (arrhythmias and sudden death) and/or mechanical function (heart failure) constitute one of the major causes of disability and death, which heavily burden the health care systems across the globe.